Quest Diagnostics (DGX) revenue breakdown
By segment, DIS business is the largest at 98% of fiscal 2025 revenue, growing 5% a year over 9 years.
By product, Routine clinical testing and other services is the largest at 40% of fiscal 2021 revenue; Gene-based and esoteric (including advanced diagnostics) testing services grew fastest, 4% a year over 5 years.
Revenue by segment
Fiscal years, as Quest Diagnostics reports them in its 10-K filings; fiscal 2025 total $11.0B.
| Segments | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DIS business | $6.8B | $7.1B | $7.2B | $7.4B | $9.1B | $10.5B | $9.6B | $9.0B | $9.6B | $10.8B | 98% |
| DS businesses | $377M | $334M | $327M | $321M | $298M | $294M | $274M | $276M | $258M | $250M | 2% |
Revenue by product
Fiscal years, as Quest Diagnostics reports them in its 10-K filings; fiscal 2021 total $10.8B.
| Products | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | Share |
|---|---|---|---|---|---|---|---|
| Routine clinical testing and other services | $3.9B | $4.0B | $4.2B | $4.2B | $3.8B | $4.3B | 40% |
| Gene-based and esoteric (including advanced diagnostics) testing services | $2.3B | $2.4B | $2.4B | $2.6B | $2.1B | $2.9B | 27% |
| COVID-19 testing services | — | — | — | — | $2.7B | $2.8B | 26% |
| Anatomic pathology testing services | $624M | $612M | $578M | $579M | $482M | $553M | 5% |
| All other services | $377M | $335M | $327M | $321M | $298M | $294M | 3% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for DGX.
Open DGX in InvestinglyQuestions
Where does Quest Diagnostics make its money?
In fiscal 2025, by segment: DIS business $10.8B, DS businesses $250M.
From Quest Diagnostics's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.